Scientists at Centre National de la Recherche Scientifique, Ecole Nationale Supérieure de Chimie de Paris, Universitat de Barcelona and Université Paris Sciences et Lettres have divulged metal complexes (particularly Ru[II]) acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, dermatological disorders and fungal infections.

Japan Tobacco Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), Alzheimer’s disease and Parkinson’s disease.

Insilico Medicine Inc. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Suzhou Longbotai Pharmaceutical Co. Ltd. has disclosed benzimidazole derivatives reported to be useful for the treatment of respiratory syncytial virus (RSV) infections.

Researchers at Anadolu University and Bilecik Seyh Edebali University have described quinazolinone derivative compounds acting as EGFR (HER1; erbB1) inhibitors and apoptosis inducers reported to be useful for the treatment of lung cancer.

Signet Therapeutics Co. Ltd. has divulged α, β-unsaturated amide compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Scientists at Livzon Pharmaceutical Group Inc., Shanghai Institute of Organic Chemistry and the University of Michigan have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bound to a cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) targeting moiety through a linker reported to be useful for the treatment of cancer.

The State University of New Jersey (Rutgers) has synthesized non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.

KU Leuven has disclosed exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of cancer, among others.

Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.